BALTIMORE, MD, January 16, 2025 – Intensive care units (ICUs) face mounting pressure to effectively manage resources while delivering optimal patient care. Groundbreaking research published in the INFORMS journal Information Systems Research highlights how a novel artificial intelligence (AI) model is revolutionizing ICU care by not only improving predictions of patient length of stay, but also equipping clinicians with clear, evidence-based insights to guide critical decisions.
Cutting-edge chips, especially those designed to power emerging AI applications, tend to receive the most attention in the media and generate the most excitement. However, so-called “legacy” chips are just as important — if not more — to our daily lives.
January is National Blood Donor Month and, not coincidentally, a time when donations tend to ebb. Every two seconds, someone in the U.S. needs blood for serious injuries, childbirth, cancer treatments and more, according to the Department of Health and Human Services.
An audio journey of how data and analytics save lives, save money and solve problems.
Ashley Smith
Public Affairs Coordinator
INFORMS
Catonsville, MD
[email protected]
443-757-3578
Explore our resources for multiple topics including:
The airline industry has been a major beneficiary of the vaccine euphoria. First Pfizer, then Moderna announced vaccine candidates with a promised effectiveness of 90% or more. This excited investors and airline executives alike, with visions of pent-up demand creating packed planes with filled middle seats.
Another wave of COVID-19 cases is now triggering another wave of panic buying across the country. But the Maryland Department of Commerce says it has no regulatory oversight on grocers in the state. At this point, it's up to each individual company to set purchasing limits on high-demand items. In some instances, stores are starting to see empty shelves again.
Scientists work at the mAbxience biosimilar monoclonal antibody laboratory plant in Garin, Buenos Aires province, on August 14, 2020, where an experimental coronavirus vaccine will be produced for Latin America. - Argentina will manufacture while Mexico will pack and distribute in Latin America, except of Brazil, the vaccine against COVID-19 developed by the University of Oxford and the AstraZeneca laboratory.
Two drug companies have now reported highly successful results from phase III trials of COVID-19 vaccines. On November 18 Pfizer and partner BioNTech said their vaccine was 95 percent effective at preventing the disease, based on full trial results. Two days earlier Moderna reported its vaccine was 94.5 percent effective, based on interim data.
It’s probably not exactly what President Donald Trump meant when he borrowed the historic jingoistic slogan “America First” for his administration, but since early in the global COVID-19 pandemic, the U.S. has consistently held the Number One spot in coronavirus cases and deaths. It took less than two months for these numbers to grow from 200,000 to a mind-boggling 250,000 now.
OR/MS Today is the INFORMS member magazine that shares the latest research and best practices in operations research, analytics and the management sciences.
Access OR/MS Today Magazine
Analytics magazine showcases articles and research reports based on big data, AI, machine learning, data analytics and other new-age technologies.
Access Analytics Magazine